According to preclinical research published in Cell, researchers with City of Hope discovered that a type of human immune cells known to be important for allergy and other immune responses—human type 2 innate lymphoid cells, or ILC2s—can also attack cancer.
Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.
